HopeStage
Back to all studies
TerminatedNCT00867360

Treatment of Psychotic Major Depression With Mifepristone

Researchers are comparing Mifepristone (RU-486) and placebo to find out how the approaches affect psychotic symptoms in people with depression.

Medication studyAges 21–85United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing Mifepristone (RU-486) and placebo to find out how the approaches affect psychotic symptoms in people with depression.

Who could participate?

Listed age limits: 21 years to 85 years.

Listed locations
StanfordSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateAugust 2005
Recruitment status
Terminated
Enrollment listed in the registry
10
Sponsor
Stanford University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 21 Years to 85 Years
Official registry ID
NCT00867360
Official title
Show the full official title

Hypothalamic-Pituitary-Adrenal (HPA)/Dopamine Axis in Psychotic Depression

Recruitment & locations

Terminated

Stanford

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Mifepristone (RU-486) and placebo to find out how the approaches affect psychotic symptoms in people with depression.

Who is behind this study?

The study sponsor is Stanford University, a university.

Does this study involve medication?

Yes. The study involves medication, including Mifepristone (RU-486) and Placebo.

Who can participate?

Listed age limits: 21 years to 85 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies